Model for Predicting the Effect of Sibutramine Therapy in Obesity

被引:0
|
作者
Danilov, Sergey D. [1 ]
Matveev, Georgiy A. [1 ]
Babenko, Alina Yu. [1 ]
Shlyakhto, Evgeny V. [1 ]
机构
[1] Almazov Natl Med Res Ctr, WCRC Ctr Personalized Med, Lab Prediabet & Metab Disorders, St Petersburg 197341, Russia
来源
JOURNAL OF PERSONALIZED MEDICINE | 2024年 / 14卷 / 08期
关键词
obesity; prediction model; sibutramine; XGBoost classification; Shapley data valuation;
D O I
10.3390/jpm14080811
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The development of models predicting response to weight loss therapy using sibutramine is found in only a few cases. The objective of the work is to develop a data-driven method of personalized recommendation for obesity treatment that would predict the response to sibutramine based on the current set of patient parameters. Methods: The decision system is built on the XGBoost classification algorithm along with recursive feature selection and Shapley data valuation. Using the results of clinical trials, it was trained to estimate the probability of overcoming a weight loss threshold. The model was evaluated by the accuracy metric using the Leave-One-Out cross-validation. Results: The model for predicting response to sibutramine treatment over 3 months has an accuracy of 71%. The model for predicting outcomes at the sixth month visit based on results at 3 months has an accuracy of 80%. Conclusions: Although our developed prediction model may not exhibit high precision compared to certain benchmarks, it significantly outperforms random chance or models relying only on BMI parameters. Our model used the available range of laboratory tests, which makes it possible to use this model for routine clinical use and help doctors decide whether to prescribe sibutramine.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Discussion Panel 2: The role of sibutramine in the treatment of obesity
    GuyGrand, B
    Stock, M
    Lean, M
    Astrup, A
    Contaldo
    Carruba
    Kolanowski
    Milewicz
    Barranco
    INTERNATIONAL JOURNAL OF OBESITY, 1997, 21 : S37 - S39
  • [32] Elevation of QT dispersion after obesity drug sibutramine
    Yalcin, Ahmet A.
    Yavuz, Bunyamin
    Ertugrul, Derun T.
    Algul, Beyza
    Yilmaz, Hamiyet
    Deveci, Onur S.
    Kucukazman, Metin
    Ata, Naim
    Demirel, Gokhan
    Dal, Kursat
    Tutal, Emre
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2010, 11 (11) : 832 - 835
  • [34] A Benefit-Risk Assessment of Sibutramine in the Management of Obesity
    Enzo Nisoli
    Michele O. Carruba
    Drug Safety, 2003, 26 : 1027 - 1048
  • [35] FDA approval of sibutramine - an important milestone in obesity management
    不详
    SOUTH AFRICAN MEDICAL JOURNAL, 1998, 88 : C57 - C57
  • [36] Drug Treatment for Obesity in the Post-Sibutramine Era
    Cheung, Bernard M. Y.
    DRUG SAFETY, 2011, 34 (08) : 641 - 650
  • [37] Combining behavior modification and sibutramine for the treatment of obesity.
    Phelan, S
    Wadden, TA
    Wang, SS
    Sarwer, DB
    Womble, LG
    Berkowitz, RI
    Rothman, R
    OBESITY RESEARCH, 2001, 9 : 198S - 198S
  • [38] Dynamic Model Predicting Overweight, Obesity, and Extreme Obesity Prevalence Trends
    Thomas, Diana Maria
    Weederman, Marion
    Fuemmeler, Bernard
    Martin, Corby
    Dhurandhar, Nikhil
    Bredlau, Carl
    Heymsfield, Steven B.
    Ravussin, Eric
    Bouchard, Claude
    FASEB JOURNAL, 2013, 27
  • [39] Dynamic Model Predicting Overweight, Obesity, and Extreme Obesity Prevalence Trends
    Thomas, Diana M.
    Weedermann, Marion
    Fuemmeler, Bernard F.
    Martin, Corby K.
    Dhurandhar, Nikhil V.
    Bredlau, Carl
    Heymsfield, Steven B.
    Ravussin, Eric
    Bouchard, Claude
    OBESITY, 2014, 22 (02) : 590 - 597
  • [40] Metabolic benefits associated with sibutramine therapy
    Krejs G.J.
    International Journal of Obesity, 2002, 26 (Suppl 4) : S34 - S37